Advair
Product Images NDC 33261-873

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Advair (NDC 33261-873). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aidarex Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1. Cumulative Incidence Of Asthma-related Deaths In The 28-week Salmeterol Multi-center Asthma Research Trial (smart), By Duration Of Treatment (Advair Diskus For Glaxosmithkline 1)

Figure 1. Cumulative Incidence Of Asthma-related Deaths In The 28-week Salmeterol Multi-center Asthma Research Trial (smart), By Duration Of Treatment (Advair Diskus For Glaxosmithkline 1)
A multi-panel line graph showing cumulative incidence of asthma-related death over treatment duration in days. The top panel represents all subjects, the middle panel represents Caucasian subjects, and the bottom panel represents African American subjects, comparing salmeterol versus placebo groups. Each panel includes patient numbers at risk at various time points.*
FDA Label Image

Figure 1 (Advair Diskus For Glaxosmithkline 10)

Figure 1 (Advair Diskus For Glaxosmithkline 10)
The image shows a partial view of an ADVAIR DISKUS inhaler device, a dry powder inhalation system. The device is gray and features a round label area with text that is not fully legible. It includes the activation lever and mouthpiece sections typical of a Diskus inhaler. The labeler Aidarex Pharmaceuticals LLC is known from the product data but is not visible on the device in this image.*
FDA Label Image

Figure 2 (Advair Diskus For Glaxosmithkline 11)

Figure 2 (Advair Diskus For Glaxosmithkline 11)
An instructional illustration showing a hand holding an ADVAIR DISKUS inhaler, demonstrating the proper gripping technique with an arrow indicating the direction to rotate or open the device.*
FDA Label Image

Figure 3 (Advair Diskus For Glaxosmithkline 12)

Figure 3 (Advair Diskus For Glaxosmithkline 12)
Illustration showing a hand holding an ADVAIR DISKUS inhaler while demonstrating the device's twisting and opening mechanism with an arrow indicating the motion to prepare it for use.*
FDA Label Image

Figure 4 (Advair Diskus For Glaxosmithkline 13)

Figure 4 (Advair Diskus For Glaxosmithkline 13)
An illustration showing a person holding an inhaler device near their mouth, demonstrating how to use it. The image appears instructional, likely related to the administration of inhaled medications.*
FDA Label Image

Figure 5 (Advair Diskus For Glaxosmithkline 14)

Figure 5 (Advair Diskus For Glaxosmithkline 14)
An instructional illustration showing a woman holding an ADVAIR DISKUS inhaler near her mouth, demonstrating the proper use of the device for inhalation.*
FDA Label Image

Figure 6 (Advair Diskus For Glaxosmithkline 15)

Figure 6 (Advair Diskus For Glaxosmithkline 15)
An instructional illustration showing hands holding an ADVAIR DISKUS inhaler device. The image highlights how to properly hold and operate the disk-shaped inhaler by applying a twisting motion as indicated by an arrow.*
FDA Label Image

Image Label (Advair Diskus For Glaxosmithkline 16)

Image Label (Advair Diskus For Glaxosmithkline 16)
Packaging label for ADVAIR DISKUS 100/50MCG inhalation powder, provided in 60 doses. Label shows Aidarex Pharmaceuticals LLC as the distributor and GlaxoSmithKline as the manufacturer. It lists active ingredients: fluticasone propionate 100MCG and salmeterol 50MCG, specifies the product as generic for ADVAIR DISKUS, and includes NDC 33261-0873-01.*
FDA Label Image

Image Label (Advair Diskus For Glaxosmithkline 17)

Image Label (Advair Diskus For Glaxosmithkline 17)
Label for ADVAIR DISKUS inhalation powder, 250/50 MCG strength, with 60 doses per inhaler. Active ingredients listed are fluticasone propionate 250 MCG and salmeterol 50 MCG. The label also includes information about the manufacturer GlaxoSmithKline and distributor Aidarex Pharmaceuticals LLC, alongside the National Drug Code (NDC) 33261-0874-01.*
FDA Label Image

Fluticasone Propionate Chemical Structure (Advair Diskus For Glaxosmithkline 2)

Fluticasone Propionate Chemical Structure (Advair Diskus For Glaxosmithkline 2)
Chemical structure diagram of ADVAIR DISKUS active ingredients, showing a detailed molecular structure with various chemical groups and bonds displayed.*
FDA Label Image

Salmeterol Xinafoate Chemical Structure (Advair Diskus For Glaxosmithkline 3)

Salmeterol Xinafoate Chemical Structure (Advair Diskus For Glaxosmithkline 3)
Chemical structure diagram showing molecular formulas of active ingredients likely associated with ADVAIR DISKUS, including a corticosteroid and a beta-agonist compound. The structure features phenol groups, hydroxyl groups, and carboxylic acid functional groups.*
FDA Label Image

Figure 2. Mean Percent Change From Baseline In Fev1 In Patients With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (study 1) (Advair Diskus For Glaxosmithkline 4)

Figure 2. Mean Percent Change From Baseline In Fev1 In Patients With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (study 1) (Advair Diskus For Glaxosmithkline 4)
A line graph comparing the percentage change in FEV1 over 12 weeks among four groups: ADVAIR DISKUS 100/50 twice daily, Fluticasone propionate 100 mcg twice daily, Salmeterol 50 mcg twice daily, and Placebo. The graph shows each treatment group's changes week by week and ends with a tabulated number of participants (N) for each group at baseline, week 6, week 12, and the endpoint.*
FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Patients With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (study 1) (Advair Diskus For Glaxosmithkline 5)

Figure 3. Percent Change In Serial 12-hour Fev1 In Patients With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (study 1) (Advair Diskus For Glaxosmithkline 5)
A line graph showing the percentage change in FEV1 over 12 hours following treatment with ADVAIR DISKUS 100/50 twice daily compared to salmeterol 50 mcg twice daily, fluticasone propionate 100 mcg twice daily, and placebo. The graph tracks the changes over time from Day 1 baseline up to 12 hours.*
FDA Label Image

Figure 4. Percent Change In Serial 12-hour Fev1 In Patients With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (study 1) (Advair Diskus For Glaxosmithkline 6)

Figure 4. Percent Change In Serial 12-hour Fev1 In Patients With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (study 1) (Advair Diskus For Glaxosmithkline 6)
A line graph showing the percentage change in FEV1 relative to Day 1 baseline over a 12-hour period, comparing ADVAIR DISKUS 100/50 twice daily, Salmeterol 50 mcg twice daily, Fluticasone propionate 100 mcg twice daily, and placebo. ADVAIR DISKUS shows the highest increase in FEV1 starting from Day 1 and peaking shortly after.*
FDA Label Image

Figure 5. Predose Fev1: Mean Percent Change From Baseline In Patients With Chronic Obstructive Pulmonary Disease (Advair Diskus For Glaxosmithkline 7)

Figure 5. Predose Fev1: Mean Percent Change From Baseline In Patients With Chronic Obstructive Pulmonary Disease (Advair Diskus For Glaxosmithkline 7)
A line graph comparing the percentage change in FEV1 over a 24-week period for ADVAIR DISKUS 250/50 twice daily, Salmeterol 50 mcg twice daily, and placebo. The graph includes baseline FEV1 values and sample sizes for each group at various time points.*
FDA Label Image

Figure 6. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Patients With Chronic Obstructive Pulmonary Disease (Advair Diskus For Glaxosmithkline 8)

Figure 6. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Patients With Chronic Obstructive Pulmonary Disease (Advair Diskus For Glaxosmithkline 8)
A line graph depicting the percentage change in FEV1 over 24 weeks for ADVAIR DISKUS 250/50 mcg, fluticasone propionate 250 mcg, and placebo groups. The graph shows data points from Day 1 through Week 24, illustrating FEV1 changes for each treatment group along with sample sizes at multiple time points.*
FDA Label Image

Diskus Parts (Advair Diskus For Glaxosmithkline 9)

Diskus Parts (Advair Diskus For Glaxosmithkline 9)
An illustration of the ADVAIR DISKUS inhaler showing labeled parts: Lever, Mouthpiece, Dose Indicator, Thumbgrip, and Outer Case. The center label displays the strengths 100/50 and identifies the product as ADVAIR DISKUS containing fluticasone propionate and salmeterol inhalation powder.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.